Central Nervous System Agents in Medicinal Chemistry
Title:Meet Our Associate Board Member
Volume: 20 Issue: 1
Author(s): Majid Asadi-Shekaari
Affiliation:
Export Options
About this article
Cite this article as:
Asadi-Shekaari Majid, Meet Our Associate Board Member, Central Nervous System Agents in Medicinal Chemistry 2020; 20 (1) . https://dx.doi.org/10.2174/187152492001200303164412
DOI https://dx.doi.org/10.2174/187152492001200303164412 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
15
2
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melanocortin-4 Receptor Antagonists for the Treatment of Depression and Anxiety Disorders
Current Topics in Medicinal Chemistry Angelica Injection Improves Functional Recovery and Motoneuron Maintenance with Increased Expression of Brain Derived Neurotrophic Factor and Nerve Growth Factor
Current Neurovascular Research Molecular Targeting Regulation of Proliferation and Differentiation of the Bone Marrow-Derived Mesenchymal Stem Cells or Mesenchymal Stromal Cells
Current Drug Targets Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Gene-environment Interactions in Late Life: Linking Psychosocial Stress with Brain Aging
Current Neuropharmacology Cannabinoids and Psychosis
Current Pharmaceutical Design The AMPAR Antagonist Perampanel Regulates Neuronal Necroptosis via Akt/GSK3β Signaling After Acute Traumatic Injury in Cortical Neurons
CNS & Neurological Disorders - Drug Targets PSEN1 Promoter Demethylation in Hyperhomocysteinemic TgCRND8 Mice is the Culprit, not the Consequence
Current Alzheimer Research EDITORIAL (Thematic Issue: New Targets of Medical Treatment in Psychiatric Disorders)
Current Neuropharmacology Neurobiology of Depression and Novel Antidepressant Drug Targets
Current Pharmaceutical Design From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario
Current Drug Targets Alpha 4 Integrin Antagonists
Current Pharmaceutical Design Serotonin 5-HT<sub>1A</sub> Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs
Current Pharmaceutical Design Opportunities to Discover Genes Regulating Depression and Antidepressant Response from Rodent Behavioral Genetics
Current Pharmaceutical Design Metabotropic Glutamate Receptor Dependent Cortical Plasticity in Chronic Pain
Current Neuropharmacology Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Diagnosis of Drug-Induced Liver Disease
Current Clinical Pharmacology Frontal Lobe Synaptic Plasticity in Development and Disease: Modulation by the Dopamine D1 Receptor
Current Pharmaceutical Design Disorder-Specific Emotional Imagery for Differential and Quantitative Assessment of Agoraphobia
Current Pharmaceutical Design Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders
Current Drug Metabolism